Abstract
The EANM Congress 2014 took place in Gothenburg, Sweden, from 18 to 22 October under the presidency of Prof. Wim Oyen, chair of the EANM Scientific Committee. Prof. Peter Gjertsson chaired the Local Organizing Committee, according to the standardized EANM congress structure. The meeting was a highlight for the multidisciplinary community that forms the heart and soul of nuclear medicine; attendance was exceptionally high. In total almost 5,300 participants came to Gothenburg, and 1,397 colleagues participated via the EANM LIVE sessions (http://eanmlive.eanm.org/index.php). Participants from all continents were presented with an excellent programme consisting of symposia, scientific and featured sessions, CME sessions, and plenary lectures. These lectures were devoted to nuclear medicine therapy, hybrid imaging and molecular life sciences. Two tracks were included in the main programme, clustering multi-committee involvement: the 5th International Symposium on Targeted Radionuclide-therapy and Dosimetry (ISTARD) and the first Molecules to Man (M2M) track, an initiative of the EANM Committees for Translational Molecular Imaging, Radiopharmacy and Drug Development. The industry made a substantial contribution to the success of the congress demonstrating the latest technology and innovations in the field. During the closing Highlights Lecture, a selection of the best-rated abstracts was presented including diverse areas of nuclear medicine: physics and instrumentation, radiopharmacy, preclinical imaging, oncology (with a focus on the clinical application of newly developed tracers) and radionuclide therapy, cardiology and neurosciences. This Highlights Lecture could only be a brief summary of the large amount of data presented and discussed during the meeting, which can be found in much greater detail in the congress proceedings book, published as Volume 41, Supplement 2 of the European Journal of Nuclear Medicine and Molecular Imaging in October 2014.
Highlights
The 27th Annual Congress of the European Association of Nuclear Medicine (EANM) took place in Gothenburg, Sweden on 18 – 22 October 2014 under the chairmanship of Prof
While up to 70 % loss in patients with early Parkinson’s disease (PD) occurs in the putamen, high-resolution PET showed that the dopamine transporter (DAT) signal in the substantia nigra (SN) can be quantified, but with much lower abnormality, indicating that the integrity of the SN cell bodies is relatively preserved and that in PD mainly the terminals are affected in the early disease course
The EANM 2014 Congress provided a sample of such novel nuclear medicine contributions with excellent innovations inclinical imaging methodology, physics, radiopharmaceuticals and radiochemistry
Summary
The 27th Annual Congress of the European Association of Nuclear Medicine (EANM) took place in Gothenburg, Sweden on 18 – 22 October 2014 under the chairmanship of Prof. Wim Oyen, chair of the EANM Scientific Committee, and Prof. Peter Gjertsson, chair of the Local Organizing Committee. The meeting provided a forum for discussion for those working in the broad field of nuclear medicine in Europe and the rest of the world. The programme reflected the recent progress in this rapidly evolving field. Scientists coming from 82 countries shared their knowledge and presented and discussed new scientific results. The programme was of excellent quality and was based on the standardized EANM congress structure
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
